ArticleClinical kidney journal2025
Association between serum short-chain fatty acid levels and the risk of all-cause and cardiovascular disease mortality in Chinese patients undergoing maintenance hemodialysis: a retrospective cohort study.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Opportunities Targeting the ACE2/Ang-(1-7)/MasR Pathway in Cardiometabolic Disease.Current hypertension reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between short-chain fatty acid (SCFA) levels and the risk of all-cause and cardiovascular disease (CVD) mortality in patients undergoing maintenance hemodialysis (MHD) is inconclusive. Furthermore, no studies on the significance of SCFA levels in MHD patients have been conducted in China. Therefore, this association was investigated in MHD patients. Methods: In this retrospective cohort study, 260 MHD patients were followed up at Central Hospital of Dalian University of Technology between January 2015 and December 2017. Serum SCFA levels were categorized into three tertiles, and the lowest tertile served as the reference group. Survival curves were obtained using the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard models. Results: There were 141 all-cause deaths during the follow-up period of (91.00 ± 0.84) months, of which 85 were due to CVDs. Kaplan-Meier analysis revealed that the risk of CVD mortality in the highest tertile of serum butyric acid level was significantly lower than that in the lowest tertile (log-rank Conclusion: Serum butyric acid level was associated with lower risk of CVD mortality among MHD patients. Further prospective large-scale studies are needed to confirm this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.